Global Companion Cancer Diagnostics Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Companion Cancer Diagnostics market size was valued at US$ million in 2023. With growing demand in downstream market, the Companion Cancer Diagnostics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Companion Cancer Diagnostics market. Companion Cancer Diagnostics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Companion Cancer Diagnostics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Companion Cancer Diagnostics market.
A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Companion Cancer Diagnostics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Companion Cancer Diagnostics market. It may include historical data, market segmentation by Type (e.g., Breast Cancer, Lung Cancer), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Companion Cancer Diagnostics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Companion Cancer Diagnostics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Companion Cancer Diagnostics industry. This include advancements in Companion Cancer Diagnostics technology, Companion Cancer Diagnostics new entrants, Companion Cancer Diagnostics new investment, and other innovations that are shaping the future of Companion Cancer Diagnostics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Companion Cancer Diagnostics market. It includes factors influencing customer ' purchasing decisions, preferences for Companion Cancer Diagnostics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Companion Cancer Diagnostics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Companion Cancer Diagnostics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Companion Cancer Diagnostics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Companion Cancer Diagnostics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Companion Cancer Diagnostics market.
Market Segmentation:
Companion Cancer Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Companion Cancer Diagnostics market size was valued at US$ million in 2023. With growing demand in downstream market, the Companion Cancer Diagnostics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Companion Cancer Diagnostics market. Companion Cancer Diagnostics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Companion Cancer Diagnostics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Companion Cancer Diagnostics market.
A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Companion Cancer Diagnostics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Companion Cancer Diagnostics market. It may include historical data, market segmentation by Type (e.g., Breast Cancer, Lung Cancer), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Companion Cancer Diagnostics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Companion Cancer Diagnostics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Companion Cancer Diagnostics industry. This include advancements in Companion Cancer Diagnostics technology, Companion Cancer Diagnostics new entrants, Companion Cancer Diagnostics new investment, and other innovations that are shaping the future of Companion Cancer Diagnostics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Companion Cancer Diagnostics market. It includes factors influencing customer ' purchasing decisions, preferences for Companion Cancer Diagnostics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Companion Cancer Diagnostics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Companion Cancer Diagnostics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Companion Cancer Diagnostics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Companion Cancer Diagnostics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Companion Cancer Diagnostics market.
Market Segmentation:
Companion Cancer Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Gastric Cancer
- Pharmaceutical & Biopharmaceutical Companies
- Reference Laboratories
- CROs
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- F. Hoffmann-La Roche
- Agilent Technologies
- QIAGEN
- Abbott Laboratories
- Almac Group
- Danaher Corporation
- bioMйrieuxSA
- Myriad Genetics
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Companion Cancer Diagnostics Market Size 2019-2030
2.1.2 Companion Cancer Diagnostics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Companion Cancer Diagnostics Segment by Type
2.2.1 Breast Cancer
2.2.2 Lung Cancer
2.2.3 Colorectal Cancer
2.2.4 Melanoma
2.2.5 Gastric Cancer
2.3 Companion Cancer Diagnostics Market Size by Type
2.3.1 Companion Cancer Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
2.4 Companion Cancer Diagnostics Segment by Application
2.4.1 Pharmaceutical & Biopharmaceutical Companies
2.4.2 Reference Laboratories
2.4.3 CROs
2.4.4 Others
2.5 Companion Cancer Diagnostics Market Size by Application
2.5.1 Companion Cancer Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
3 COMPANION CANCER DIAGNOSTICS MARKET SIZE BY PLAYER
3.1 Companion Cancer Diagnostics Market Size Market Share by Players
3.1.1 Global Companion Cancer Diagnostics Revenue by Players (2019-2024)
3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Companion Cancer Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMPANION CANCER DIAGNOSTICS BY REGIONS
4.1 Companion Cancer Diagnostics Market Size by Regions (2019-2024)
4.2 Americas Companion Cancer Diagnostics Market Size Growth (2019-2024)
4.3 APAC Companion Cancer Diagnostics Market Size Growth (2019-2024)
4.4 Europe Companion Cancer Diagnostics Market Size Growth (2019-2024)
4.5 Middle East & Africa Companion Cancer Diagnostics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Companion Cancer Diagnostics Market Size by Country (2019-2024)
5.2 Americas Companion Cancer Diagnostics Market Size by Type (2019-2024)
5.3 Americas Companion Cancer Diagnostics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Companion Cancer Diagnostics Market Size by Region (2019-2024)
6.2 APAC Companion Cancer Diagnostics Market Size by Type (2019-2024)
6.3 APAC Companion Cancer Diagnostics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Companion Cancer Diagnostics by Country (2019-2024)
7.2 Europe Companion Cancer Diagnostics Market Size by Type (2019-2024)
7.3 Europe Companion Cancer Diagnostics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Companion Cancer Diagnostics by Region (2019-2024)
8.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2019-2024)
8.3 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMPANION CANCER DIAGNOSTICS MARKET FORECAST
10.1 Global Companion Cancer Diagnostics Forecast by Regions (2025-2030)
10.1.1 Global Companion Cancer Diagnostics Forecast by Regions (2025-2030)
10.1.2 Americas Companion Cancer Diagnostics Forecast
10.1.3 APAC Companion Cancer Diagnostics Forecast
10.1.4 Europe Companion Cancer Diagnostics Forecast
10.1.5 Middle East & Africa Companion Cancer Diagnostics Forecast
10.2 Americas Companion Cancer Diagnostics Forecast by Country (2025-2030)
10.2.1 United States Companion Cancer Diagnostics Market Forecast
10.2.2 Canada Companion Cancer Diagnostics Market Forecast
10.2.3 Mexico Companion Cancer Diagnostics Market Forecast
10.2.4 Brazil Companion Cancer Diagnostics Market Forecast
10.3 APAC Companion Cancer Diagnostics Forecast by Region (2025-2030)
10.3.1 China Companion Cancer Diagnostics Market Forecast
10.3.2 Japan Companion Cancer Diagnostics Market Forecast
10.3.3 Korea Companion Cancer Diagnostics Market Forecast
10.3.4 Southeast Asia Companion Cancer Diagnostics Market Forecast
10.3.5 India Companion Cancer Diagnostics Market Forecast
10.3.6 Australia Companion Cancer Diagnostics Market Forecast
10.4 Europe Companion Cancer Diagnostics Forecast by Country (2025-2030)
10.4.1 Germany Companion Cancer Diagnostics Market Forecast
10.4.2 France Companion Cancer Diagnostics Market Forecast
10.4.3 UK Companion Cancer Diagnostics Market Forecast
10.4.4 Italy Companion Cancer Diagnostics Market Forecast
10.4.5 Russia Companion Cancer Diagnostics Market Forecast
10.5 Middle East & Africa Companion Cancer Diagnostics Forecast by Region (2025-2030)
10.5.1 Egypt Companion Cancer Diagnostics Market Forecast
10.5.2 South Africa Companion Cancer Diagnostics Market Forecast
10.5.3 Israel Companion Cancer Diagnostics Market Forecast
10.5.4 Turkey Companion Cancer Diagnostics Market Forecast
10.5.5 GCC Countries Companion Cancer Diagnostics Market Forecast
10.6 Global Companion Cancer Diagnostics Forecast by Type (2025-2030)
10.7 Global Companion Cancer Diagnostics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Information
11.1.2 F. Hoffmann-La Roche Companion Cancer Diagnostics Product Offered
11.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 F. Hoffmann-La Roche Main Business Overview
11.1.5 F. Hoffmann-La Roche Latest Developments
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Information
11.2.2 Agilent Technologies Companion Cancer Diagnostics Product Offered
11.2.3 Agilent Technologies Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Agilent Technologies Main Business Overview
11.2.5 Agilent Technologies Latest Developments
11.3 QIAGEN
11.3.1 QIAGEN Company Information
11.3.2 QIAGEN Companion Cancer Diagnostics Product Offered
11.3.3 QIAGEN Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 QIAGEN Main Business Overview
11.3.5 QIAGEN Latest Developments
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Information
11.4.2 Abbott Laboratories Companion Cancer Diagnostics Product Offered
11.4.3 Abbott Laboratories Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Abbott Laboratories Main Business Overview
11.4.5 Abbott Laboratories Latest Developments
11.5 Almac Group
11.5.1 Almac Group Company Information
11.5.2 Almac Group Companion Cancer Diagnostics Product Offered
11.5.3 Almac Group Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Almac Group Main Business Overview
11.5.5 Almac Group Latest Developments
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Information
11.6.2 Danaher Corporation Companion Cancer Diagnostics Product Offered
11.6.3 Danaher Corporation Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Danaher Corporation Main Business Overview
11.6.5 Danaher Corporation Latest Developments
11.7 bioMйrieuxSA
11.7.1 bioMйrieuxSA Company Information
11.7.2 bioMйrieuxSA Companion Cancer Diagnostics Product Offered
11.7.3 bioMйrieuxSA Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 bioMйrieuxSA Main Business Overview
11.7.5 bioMйrieuxSA Latest Developments
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Information
11.8.2 Myriad Genetics Companion Cancer Diagnostics Product Offered
11.8.3 Myriad Genetics Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Myriad Genetics Main Business Overview
11.8.5 Myriad Genetics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Companion Cancer Diagnostics Market Size 2019-2030
2.1.2 Companion Cancer Diagnostics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Companion Cancer Diagnostics Segment by Type
2.2.1 Breast Cancer
2.2.2 Lung Cancer
2.2.3 Colorectal Cancer
2.2.4 Melanoma
2.2.5 Gastric Cancer
2.3 Companion Cancer Diagnostics Market Size by Type
2.3.1 Companion Cancer Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
2.4 Companion Cancer Diagnostics Segment by Application
2.4.1 Pharmaceutical & Biopharmaceutical Companies
2.4.2 Reference Laboratories
2.4.3 CROs
2.4.4 Others
2.5 Companion Cancer Diagnostics Market Size by Application
2.5.1 Companion Cancer Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
3 COMPANION CANCER DIAGNOSTICS MARKET SIZE BY PLAYER
3.1 Companion Cancer Diagnostics Market Size Market Share by Players
3.1.1 Global Companion Cancer Diagnostics Revenue by Players (2019-2024)
3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Companion Cancer Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMPANION CANCER DIAGNOSTICS BY REGIONS
4.1 Companion Cancer Diagnostics Market Size by Regions (2019-2024)
4.2 Americas Companion Cancer Diagnostics Market Size Growth (2019-2024)
4.3 APAC Companion Cancer Diagnostics Market Size Growth (2019-2024)
4.4 Europe Companion Cancer Diagnostics Market Size Growth (2019-2024)
4.5 Middle East & Africa Companion Cancer Diagnostics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Companion Cancer Diagnostics Market Size by Country (2019-2024)
5.2 Americas Companion Cancer Diagnostics Market Size by Type (2019-2024)
5.3 Americas Companion Cancer Diagnostics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Companion Cancer Diagnostics Market Size by Region (2019-2024)
6.2 APAC Companion Cancer Diagnostics Market Size by Type (2019-2024)
6.3 APAC Companion Cancer Diagnostics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Companion Cancer Diagnostics by Country (2019-2024)
7.2 Europe Companion Cancer Diagnostics Market Size by Type (2019-2024)
7.3 Europe Companion Cancer Diagnostics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Companion Cancer Diagnostics by Region (2019-2024)
8.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2019-2024)
8.3 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMPANION CANCER DIAGNOSTICS MARKET FORECAST
10.1 Global Companion Cancer Diagnostics Forecast by Regions (2025-2030)
10.1.1 Global Companion Cancer Diagnostics Forecast by Regions (2025-2030)
10.1.2 Americas Companion Cancer Diagnostics Forecast
10.1.3 APAC Companion Cancer Diagnostics Forecast
10.1.4 Europe Companion Cancer Diagnostics Forecast
10.1.5 Middle East & Africa Companion Cancer Diagnostics Forecast
10.2 Americas Companion Cancer Diagnostics Forecast by Country (2025-2030)
10.2.1 United States Companion Cancer Diagnostics Market Forecast
10.2.2 Canada Companion Cancer Diagnostics Market Forecast
10.2.3 Mexico Companion Cancer Diagnostics Market Forecast
10.2.4 Brazil Companion Cancer Diagnostics Market Forecast
10.3 APAC Companion Cancer Diagnostics Forecast by Region (2025-2030)
10.3.1 China Companion Cancer Diagnostics Market Forecast
10.3.2 Japan Companion Cancer Diagnostics Market Forecast
10.3.3 Korea Companion Cancer Diagnostics Market Forecast
10.3.4 Southeast Asia Companion Cancer Diagnostics Market Forecast
10.3.5 India Companion Cancer Diagnostics Market Forecast
10.3.6 Australia Companion Cancer Diagnostics Market Forecast
10.4 Europe Companion Cancer Diagnostics Forecast by Country (2025-2030)
10.4.1 Germany Companion Cancer Diagnostics Market Forecast
10.4.2 France Companion Cancer Diagnostics Market Forecast
10.4.3 UK Companion Cancer Diagnostics Market Forecast
10.4.4 Italy Companion Cancer Diagnostics Market Forecast
10.4.5 Russia Companion Cancer Diagnostics Market Forecast
10.5 Middle East & Africa Companion Cancer Diagnostics Forecast by Region (2025-2030)
10.5.1 Egypt Companion Cancer Diagnostics Market Forecast
10.5.2 South Africa Companion Cancer Diagnostics Market Forecast
10.5.3 Israel Companion Cancer Diagnostics Market Forecast
10.5.4 Turkey Companion Cancer Diagnostics Market Forecast
10.5.5 GCC Countries Companion Cancer Diagnostics Market Forecast
10.6 Global Companion Cancer Diagnostics Forecast by Type (2025-2030)
10.7 Global Companion Cancer Diagnostics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Information
11.1.2 F. Hoffmann-La Roche Companion Cancer Diagnostics Product Offered
11.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 F. Hoffmann-La Roche Main Business Overview
11.1.5 F. Hoffmann-La Roche Latest Developments
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Information
11.2.2 Agilent Technologies Companion Cancer Diagnostics Product Offered
11.2.3 Agilent Technologies Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Agilent Technologies Main Business Overview
11.2.5 Agilent Technologies Latest Developments
11.3 QIAGEN
11.3.1 QIAGEN Company Information
11.3.2 QIAGEN Companion Cancer Diagnostics Product Offered
11.3.3 QIAGEN Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 QIAGEN Main Business Overview
11.3.5 QIAGEN Latest Developments
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Information
11.4.2 Abbott Laboratories Companion Cancer Diagnostics Product Offered
11.4.3 Abbott Laboratories Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Abbott Laboratories Main Business Overview
11.4.5 Abbott Laboratories Latest Developments
11.5 Almac Group
11.5.1 Almac Group Company Information
11.5.2 Almac Group Companion Cancer Diagnostics Product Offered
11.5.3 Almac Group Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Almac Group Main Business Overview
11.5.5 Almac Group Latest Developments
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Information
11.6.2 Danaher Corporation Companion Cancer Diagnostics Product Offered
11.6.3 Danaher Corporation Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Danaher Corporation Main Business Overview
11.6.5 Danaher Corporation Latest Developments
11.7 bioMйrieuxSA
11.7.1 bioMйrieuxSA Company Information
11.7.2 bioMйrieuxSA Companion Cancer Diagnostics Product Offered
11.7.3 bioMйrieuxSA Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 bioMйrieuxSA Main Business Overview
11.7.5 bioMйrieuxSA Latest Developments
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Information
11.8.2 Myriad Genetics Companion Cancer Diagnostics Product Offered
11.8.3 Myriad Genetics Companion Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Myriad Genetics Main Business Overview
11.8.5 Myriad Genetics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Companion Cancer Diagnostics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Breast Cancer
Table 3. Major Players of Lung Cancer
Table 4. Major Players of Colorectal Cancer
Table 5. Major Players of Melanoma
Table 6. Major Players of Gastric Cancer
Table 7. Companion Cancer Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 10. Companion Cancer Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 12. Global Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 13. Global Companion Cancer Diagnostics Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Companion Cancer Diagnostics Revenue Market Share by Player (2019-2024)
Table 15. Companion Cancer Diagnostics Key Players Head office and Products Offered
Table 16. Companion Cancer Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Companion Cancer Diagnostics Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Companion Cancer Diagnostics Market Size Market Share by Regions (2019-2024)
Table 21. Global Companion Cancer Diagnostics Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Companion Cancer Diagnostics Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Companion Cancer Diagnostics Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Companion Cancer Diagnostics Market Size Market Share by Country (2019-2024)
Table 25. Americas Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 27. Americas Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 28. Americas Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 29. APAC Companion Cancer Diagnostics Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Companion Cancer Diagnostics Market Size Market Share by Region (2019-2024)
Table 31. APAC Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 33. APAC Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 34. APAC Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 35. Europe Companion Cancer Diagnostics Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Companion Cancer Diagnostics Market Size Market Share by Country (2019-2024)
Table 37. Europe Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 39. Europe Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 40. Europe Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 41. Middle East & Africa Companion Cancer Diagnostics Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Companion Cancer Diagnostics
Table 48. Key Market Challenges & Risks of Companion Cancer Diagnostics
Table 49. Key Industry Trends of Companion Cancer Diagnostics
Table 50. Global Companion Cancer Diagnostics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Companion Cancer Diagnostics Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Companion Cancer Diagnostics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Companion Cancer Diagnostics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 54. F. Hoffmann-La Roche Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 55. F. Hoffmann-La Roche Companion Cancer Diagnostics Product Offered
Table 56. F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. F. Hoffmann-La Roche Main Business
Table 58. F. Hoffmann-La Roche Latest Developments
Table 59. Agilent Technologies Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 60. Agilent Technologies Companion Cancer Diagnostics Product Offered
Table 61. Agilent Technologies Main Business
Table 62. Agilent Technologies Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. Agilent Technologies Latest Developments
Table 64. QIAGEN Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 65. QIAGEN Companion Cancer Diagnostics Product Offered
Table 66. QIAGEN Main Business
Table 67. QIAGEN Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. QIAGEN Latest Developments
Table 69. Abbott Laboratories Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 70. Abbott Laboratories Companion Cancer Diagnostics Product Offered
Table 71. Abbott Laboratories Main Business
Table 72. Abbott Laboratories Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Abbott Laboratories Latest Developments
Table 74. Almac Group Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 75. Almac Group Companion Cancer Diagnostics Product Offered
Table 76. Almac Group Main Business
Table 77. Almac Group Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. Almac Group Latest Developments
Table 79. Danaher Corporation Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 80. Danaher Corporation Companion Cancer Diagnostics Product Offered
Table 81. Danaher Corporation Main Business
Table 82. Danaher Corporation Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. Danaher Corporation Latest Developments
Table 84. bioMйrieuxSA Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 85. bioMйrieuxSA Companion Cancer Diagnostics Product Offered
Table 86. bioMйrieuxSA Main Business
Table 87. bioMйrieuxSA Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. bioMйrieuxSA Latest Developments
Table 89. Myriad Genetics Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 90. Myriad Genetics Companion Cancer Diagnostics Product Offered
Table 91. Myriad Genetics Main Business
Table 92. Myriad Genetics Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. Myriad Genetics Latest Developments
Table 1. Companion Cancer Diagnostics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Breast Cancer
Table 3. Major Players of Lung Cancer
Table 4. Major Players of Colorectal Cancer
Table 5. Major Players of Melanoma
Table 6. Major Players of Gastric Cancer
Table 7. Companion Cancer Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 10. Companion Cancer Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 12. Global Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 13. Global Companion Cancer Diagnostics Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Companion Cancer Diagnostics Revenue Market Share by Player (2019-2024)
Table 15. Companion Cancer Diagnostics Key Players Head office and Products Offered
Table 16. Companion Cancer Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Companion Cancer Diagnostics Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Companion Cancer Diagnostics Market Size Market Share by Regions (2019-2024)
Table 21. Global Companion Cancer Diagnostics Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Companion Cancer Diagnostics Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Companion Cancer Diagnostics Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Companion Cancer Diagnostics Market Size Market Share by Country (2019-2024)
Table 25. Americas Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 27. Americas Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 28. Americas Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 29. APAC Companion Cancer Diagnostics Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Companion Cancer Diagnostics Market Size Market Share by Region (2019-2024)
Table 31. APAC Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 33. APAC Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 34. APAC Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 35. Europe Companion Cancer Diagnostics Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Companion Cancer Diagnostics Market Size Market Share by Country (2019-2024)
Table 37. Europe Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 39. Europe Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 40. Europe Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 41. Middle East & Africa Companion Cancer Diagnostics Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Companion Cancer Diagnostics
Table 48. Key Market Challenges & Risks of Companion Cancer Diagnostics
Table 49. Key Industry Trends of Companion Cancer Diagnostics
Table 50. Global Companion Cancer Diagnostics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Companion Cancer Diagnostics Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Companion Cancer Diagnostics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Companion Cancer Diagnostics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 54. F. Hoffmann-La Roche Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 55. F. Hoffmann-La Roche Companion Cancer Diagnostics Product Offered
Table 56. F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. F. Hoffmann-La Roche Main Business
Table 58. F. Hoffmann-La Roche Latest Developments
Table 59. Agilent Technologies Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 60. Agilent Technologies Companion Cancer Diagnostics Product Offered
Table 61. Agilent Technologies Main Business
Table 62. Agilent Technologies Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. Agilent Technologies Latest Developments
Table 64. QIAGEN Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 65. QIAGEN Companion Cancer Diagnostics Product Offered
Table 66. QIAGEN Main Business
Table 67. QIAGEN Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. QIAGEN Latest Developments
Table 69. Abbott Laboratories Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 70. Abbott Laboratories Companion Cancer Diagnostics Product Offered
Table 71. Abbott Laboratories Main Business
Table 72. Abbott Laboratories Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Abbott Laboratories Latest Developments
Table 74. Almac Group Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 75. Almac Group Companion Cancer Diagnostics Product Offered
Table 76. Almac Group Main Business
Table 77. Almac Group Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. Almac Group Latest Developments
Table 79. Danaher Corporation Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 80. Danaher Corporation Companion Cancer Diagnostics Product Offered
Table 81. Danaher Corporation Main Business
Table 82. Danaher Corporation Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. Danaher Corporation Latest Developments
Table 84. bioMйrieuxSA Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 85. bioMйrieuxSA Companion Cancer Diagnostics Product Offered
Table 86. bioMйrieuxSA Main Business
Table 87. bioMйrieuxSA Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. bioMйrieuxSA Latest Developments
Table 89. Myriad Genetics Details, Company Type, Companion Cancer Diagnostics Area Served and Its Competitors
Table 90. Myriad Genetics Companion Cancer Diagnostics Product Offered
Table 91. Myriad Genetics Main Business
Table 92. Myriad Genetics Companion Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. Myriad Genetics Latest Developments
LIST OF FIGURES
Figure 1. Companion Cancer Diagnostics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Companion Cancer Diagnostics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Companion Cancer Diagnostics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Companion Cancer Diagnostics Sales Market Share by Country/Region (2023)
Figure 8. Companion Cancer Diagnostics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Companion Cancer Diagnostics Market Size Market Share by Type in 2023
Figure 10. Companion Cancer Diagnostics in Pharmaceutical & Biopharmaceutical Companies
Figure 11. Global Companion Cancer Diagnostics Market: Pharmaceutical & Biopharmaceutical Companies (2019-2024) & ($ Millions)
Figure 12. Companion Cancer Diagnostics in Reference Laboratories
Figure 13. Global Companion Cancer Diagnostics Market: Reference Laboratories (2019-2024) & ($ Millions)
Figure 14. Companion Cancer Diagnostics in CROs
Figure 15. Global Companion Cancer Diagnostics Market: CROs (2019-2024) & ($ Millions)
Figure 16. Companion Cancer Diagnostics in Others
Figure 17. Global Companion Cancer Diagnostics Market: Others (2019-2024) & ($ Millions)
Figure 18. Global Companion Cancer Diagnostics Market Size Market Share by Application in 2023
Figure 19. Global Companion Cancer Diagnostics Revenue Market Share by Player in 2023
Figure 20. Global Companion Cancer Diagnostics Market Size Market Share by Regions (2019-2024)
Figure 21. Americas Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 22. APAC Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 23. Europe Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 24. Middle East & Africa Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 25. Americas Companion Cancer Diagnostics Value Market Share by Country in 2023
Figure 26. United States Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Canada Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 28. Mexico Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 29. Brazil Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 30. APAC Companion Cancer Diagnostics Market Size Market Share by Region in 2023
Figure 31. APAC Companion Cancer Diagnostics Market Size Market Share by Type in 2023
Figure 32. APAC Companion Cancer Diagnostics Market Size Market Share by Application in 2023
Figure 33. China Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Japan Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 35. Korea Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Southeast Asia Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 37. India Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 38. Australia Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 39. Europe Companion Cancer Diagnostics Market Size Market Share by Country in 2023
Figure 40. Europe Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Figure 41. Europe Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Figure 42. Germany Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 43. France Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 44. UK Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Italy Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 46. Russia Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 47. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 51. South Africa Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 52. Israel Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Turkey Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 54. GCC Country Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 55. Americas Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 56. APAC Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 57. Europe Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 58. Middle East & Africa Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 59. United States Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 60. Canada Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 61. Mexico Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 62. Brazil Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 63. China Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 64. Japan Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 65. Korea Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 66. Southeast Asia Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 67. India Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 68. Australia Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 69. Germany Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 70. France Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 71. UK Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 72. Italy Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 73. Russia Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 74. Spain Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 75. Egypt Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 76. South Africa Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 77. Israel Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 78. Turkey Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 79. GCC Countries Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 80. Global Companion Cancer Diagnostics Market Size Market Share Forecast by Type (2025-2030)
Figure 81. Global Companion Cancer Diagnostics Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Companion Cancer Diagnostics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Companion Cancer Diagnostics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Companion Cancer Diagnostics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Companion Cancer Diagnostics Sales Market Share by Country/Region (2023)
Figure 8. Companion Cancer Diagnostics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Companion Cancer Diagnostics Market Size Market Share by Type in 2023
Figure 10. Companion Cancer Diagnostics in Pharmaceutical & Biopharmaceutical Companies
Figure 11. Global Companion Cancer Diagnostics Market: Pharmaceutical & Biopharmaceutical Companies (2019-2024) & ($ Millions)
Figure 12. Companion Cancer Diagnostics in Reference Laboratories
Figure 13. Global Companion Cancer Diagnostics Market: Reference Laboratories (2019-2024) & ($ Millions)
Figure 14. Companion Cancer Diagnostics in CROs
Figure 15. Global Companion Cancer Diagnostics Market: CROs (2019-2024) & ($ Millions)
Figure 16. Companion Cancer Diagnostics in Others
Figure 17. Global Companion Cancer Diagnostics Market: Others (2019-2024) & ($ Millions)
Figure 18. Global Companion Cancer Diagnostics Market Size Market Share by Application in 2023
Figure 19. Global Companion Cancer Diagnostics Revenue Market Share by Player in 2023
Figure 20. Global Companion Cancer Diagnostics Market Size Market Share by Regions (2019-2024)
Figure 21. Americas Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 22. APAC Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 23. Europe Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 24. Middle East & Africa Companion Cancer Diagnostics Market Size 2019-2024 ($ Millions)
Figure 25. Americas Companion Cancer Diagnostics Value Market Share by Country in 2023
Figure 26. United States Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Canada Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 28. Mexico Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 29. Brazil Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 30. APAC Companion Cancer Diagnostics Market Size Market Share by Region in 2023
Figure 31. APAC Companion Cancer Diagnostics Market Size Market Share by Type in 2023
Figure 32. APAC Companion Cancer Diagnostics Market Size Market Share by Application in 2023
Figure 33. China Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Japan Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 35. Korea Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Southeast Asia Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 37. India Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 38. Australia Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 39. Europe Companion Cancer Diagnostics Market Size Market Share by Country in 2023
Figure 40. Europe Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Figure 41. Europe Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Figure 42. Germany Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 43. France Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 44. UK Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Italy Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 46. Russia Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 47. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Companion Cancer Diagnostics Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 51. South Africa Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 52. Israel Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Turkey Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 54. GCC Country Companion Cancer Diagnostics Market Size Growth 2019-2024 ($ Millions)
Figure 55. Americas Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 56. APAC Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 57. Europe Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 58. Middle East & Africa Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 59. United States Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 60. Canada Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 61. Mexico Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 62. Brazil Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 63. China Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 64. Japan Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 65. Korea Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 66. Southeast Asia Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 67. India Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 68. Australia Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 69. Germany Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 70. France Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 71. UK Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 72. Italy Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 73. Russia Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 74. Spain Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 75. Egypt Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 76. South Africa Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 77. Israel Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 78. Turkey Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 79. GCC Countries Companion Cancer Diagnostics Market Size 2025-2030 ($ Millions)
Figure 80. Global Companion Cancer Diagnostics Market Size Market Share Forecast by Type (2025-2030)
Figure 81. Global Companion Cancer Diagnostics Market Size Market Share Forecast by Application (2025-2030)
